Psychopharmacology Maastricht
The psychopharmacology department at Maastricht University focuses on the cognitive, behavioral, and biological effects of various substances, ranging from pharmaceutical to recreational drugs.
Learn More
Maastricht Psychedelic Symposium
On May 24, the Maastricht Psychedelic Research Team organized a mini-symposium on psychedelics. We welcomed two international speakers: Prof. dos Santos and Prof. Bouso from Brazil and Spain to discuss their ayahuasca and ibogaine research. We also had several internal speakers: presenting on mystical vs. autobiographical psychedelic experiences (Dr Kangaslampi), microdosing (Ms. Haijen), and 5-MeO-DMT (Mr. Reckweg).
Click below to watch the entire symposium
Read about our new paper on the neurological origins of a visual psychedelic hallucination
Congratulations to Zeus Tipado on his newly published paper that introduces a new theory as to why a person experiences a visual trip on psychedelics.
Read The PaperParticipate in our studies!
We're always conducting research in our department and we're frequently looking for participants to be a part of science! If you're interested, look at the studies that we are currently conducting.
View All Studies
Our Scientists
Prof. Jan Ramaekers
I work as a professor in psychopharmacology at Maastricht University in the Netherlands. My research combines methods from psychopharmacology, forensic toxicology and cognitive neuroscience to determine drug induced changes in human performance.
Dr. Conny Quaedflieg
Stress Resilience, Intentional Forgetting, EEG
Through my extensive research experience, I have built expertise in various disciplines (psychology, psychophysiology, neurosciences) and I have become enthusiastic about bridging them.
Dr. Kim Kuypers
Microdosing, Cognition, Nutrition
My research focuses on the neurobiology of flexible cognition, empathy, and well-being.
Zain Gangaram, MSc
My research is multifaceted and is based on an RDoC model for Reactive Aggression (RA).
Dr. C. Rob Markus
I became an expert on the relation between stress, brain (gene) vulnerability and the development of cognitive-affective complaints/disorders as well as in testing (claims about) dietary treatment/assessment methods.
Sarah Roche, MSc
Psilocybin, Sustainability, Environment
My PhD research focuses on psychedelic drugs as a tool to investigate the cognitive mechanisms underlying changes in sustainable behavior.
Dr. Rudy Schreiber
CNS Drug Discovery, Research Domain Criteria
I started my career in central nervous system drug discovery in 1993 and subsequently progressed from bench scientist to senior leadership roles at global pharmaceutical companies
Prof. Arjan Blokland
Cognition, Learning & Memory, Acetylcholine
I studied Psychology at the Radboud University (Nijmegen, NL). After receiving my PhD in Maastricht in 1992, I did a post doc at the University of Cambridge in 1992.
Pablo Mallaroni, MSc
Psychedelics, fMRI/MRS, Idiosyncracy
I am PhD candidate with the Psychopharmacology Unit of Maastricht University with a background in translational neuroscience.
Psychedelic Research
Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution
cognitive, Ayahuasca, ego dissolution
→
Psilocybin induces acute and persisting alterations in immune status and the stress response in healthy volunteers
→
Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking
Ayahuasca, creativity, divergent thinking, convergent thinking
→
Spontaneous and deliberate creative cognition during and after psilocybin exposure
creativity, Cognition, Psilocybin
→
Visual hallucinations originating in the retinofugal pathway under clinical and psychedelic conditions
Psychedelics, vision, retinofugal, tripping, hallucinations, visual
→
Cannabis Research
Comparison of Cannabinoid Pharmacokinetic Properties in Occasional and Heavy Users Smoking a Marijuana or Placebo Joint
→
Cognition and motor control as a function of 9-THC concentration in serum and oral fluid: Limits of impairment
→
Medicinal Δ9-tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standard Field Sobriety Tests
→
Get in Touch
We are always up for communicating with people that have interesting ideas or questions. If you want to contact our department, please reach out using this form below.